Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein

Journal of Thoracic and Cardiovascular Surgery

Volumn 123, Issue 1, 2002, Pages 168-174

  Frese, Steffen ^a   Brunner, Thomas ^a   Gugger, Mathias ^a   Uduehi, Aima ^a   Schmid, Ralph A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CASPASE 8; CASPASE 8 INHIBITORY PROTEIN; CASPASE INHIBITOR; CISPLATIN; DOXORUBICIN; FLUOROURACIL; LIPOCORTIN 5; PACLITAXEL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0036383251     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2002.119694     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31, 1.
2. Johnson DH. Combined-modality therapy for unresectable, stage III non-small-cell lung cancer - caveat emptor or caveat venditor? [editorial] J Nail Cancer Inst. 1996;88:1175-7.
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis, lmmunity. 1995;3:673-82.
4. Ashkenazi A, Pal RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104:155-62.
5. Walczak- H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-63.
6. McCullagh P, Nelder JA. Generalized linear model. 2nd ed. Monographs on statistics and applied probability. London; Chapman and Hall: 1989.
7. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000;60:553-9.
8. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M,. Krammer PH,. et al. Cytotoxicity -dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995; 14:5579-88.
9. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-65.
10. Walczak H, Krammer PH. The CD95 (APO- I/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58-66.
11. Havell EA, Fiers W. North RJ. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med. 1988; 167:1067-85.
12. Ogasawara J. Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice [published erratum appears in Nature 1993;365:568]. Nature. 1993:364:806-9.
13. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin lmmunol. 1998:10:559-63.
14. Keane 14.Keane MM, Ettenberg SA. Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999;59:734-41.
15. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 1999;59:6153-8.
16. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer. 1999;83:151-6.
17. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med. 1999;5:146-7
18. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-5.
19. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 1999;59:2747-53.
20. Nagaraju K, Casciola-Rosen L, Rosen A, Thompson C, Loeffler L, Parker T, et al. The inhibition of apoptosis in myositis and in normal muscle cells. J lmmunol. 2000; 164:5459-65.
21. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLlCE FLICE-inhibitory protein. J Exp Med. 1999; 190:1033-8.
22. Djerbi M, Screpanti V, Catrina Al, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE -inhibitory protein defines a new class of tumor progression factors. J Exp Med. 1999; 190:1025-32.